Ivabradine Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ivabradine Hydrochloride |
| DrugBank ID | DB09083 |
| Brand Names (EU) | Ivabradine Accord |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.79% |
Approved Indication (EMA)
Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated : - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hypertrichosis (disease) | 99.79% | DL |
| 2 | Ambras type hypertrichosis universalis congenita | 99.72% | DL |
| 3 | malformation syndrome with odontal and/or periodontal component | 99.72% | DL |
| 4 | syndrome with a Dandy-Walker malformation as major feature | 99.70% | DL |
| 5 | isolated genetic hair shaft abnormality | 99.69% | DL |
| 6 | nephrogenic syndrome of inappropriate antidiuresis | 99.08% | DL |
| 7 | pulmonary hypertension | 98.50% | DL |
| 8 | familial isolated trichomegaly | 98.38% | DL |
| 9 | kyphoscoliotic heart disease | 98.18% | DL |
| 10 | leprosy | 98.03% | DL |
| 11 | benign prostatic hyperplasia (disease) | 97.69% | DL |
| 12 | persistent Mullerian duct syndrome | 96.32% | DL |
| 13 | genetic alopecia | 96.00% | DL |
| 14 | pulmonary hypertension, primary, autosomal recessive | 95.85% | DL |
| 15 | obsolete patella aplasia, coxa vara, and tarsal synostosis | 95.77% | DL |
| 16 | pneumocystosis | 95.35% | DL |
| 17 | mycotic corneal ulcer | 95.22% | DL |
| 18 | coronary artery disease | 95.13% | DL |
| 19 | familial clubfoot due to 17q23.1q23.2 microduplication | 95.10% | DL |
| 20 | anomalous left coronary artery from the pulmonary artery | 95.09% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.